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Treating alcohol use disorders (AUD) is critical in individuals suffering from hepatitis C infection (HCV). Aside from
psychosocial interventions, pharmacological treatment is effective for decreasing alcohol consumption and
promoting abstinence. However, unique factors belonging to HCV-infected individuals, such as baseline hepatic
vulnerability and possible ongoing hepatitis C treatment, complicate AUD drug therapy. The goal of this review is
to systematically identify, summarize, and evaluate the existing evidence on the pharmacological management of
AUD in HCV-infected individuals. MEDLINE, Embase, PsycINFO, and the Cochrane Central Register of Controlled Trials
were searched for English- and French-language articles published from 1993 to December 2013. The search criteria
focused on clinical trials and observational studies assessing the efficacy and/or safety of pharmacological management
of AUD in patients infected with HCV. Of 421 identified studies, three were included for analysis. Two were observational
studies assessing the safety of disulfiram. One was a randomized controlled trial assessing the efficacy and safety of
baclofen. There is paucity of data regarding the efficacy and safety of pharmacological treatment of AUD in HCV-infected
individuals, with studies being small series and showing significant heterogeneity. No strong recommendations can be
made based on the current studies as to which pharmacological option should be preferred in this sub-population.
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Extensive literature has emerged on the dangers of alco-
hol consumption in patients suffering from hepatitis C
virus (HCV) infection. Alcohol use disorders (AUD) are
more likely to occur in HCV(+) patients than in the gen-
eral population [1-3]. In turn, patients with AUD are 3
to 30 times more likely to be HCV(+) compared with
the general population (5–50% prevalence) [4], making
the comorbid association a frequently encountered clin-
ical challenge. This is of even greater importance given
the synergistic interaction of both conditions on the de-
velopment of liver pathology [5-7]. Approximately 80
percent of all HCV-infected individuals will progress to
chronic HCV infection. Of these, 10–15 percent will ad-
vance to cirrhosis within the first 20 years. Cirrhotic* Correspondence: didier.jutras-aswad@umontreal.ca
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(http://creativecommons.org/publicdomain/zeroindividuals are, in turn, at increased risk of developing
hepatocellular carcinoma [8]. Patients with chronic HCV
infection and superimposed AUD develop accelerated fi-
brosis, as well as higher rates of cirrhosis, liver failure,
and hepatocellular carcinoma, compared to HCV(+) pa-
tients who do not drink or to HCV(-) drinkers [4,9].
Moreover, alcohol consumption reduces the effective-
ness of interferon-based therapies [4,9,10]. This may be
explained by biological mechanisms, such as increased
viral resistance [11] and altered immunity [12], but also
by lower compliance and higher dropout rates in pa-
tients with AUD [13,14]. This, combined with the psy-
chiatric effects of HCV treatment, predisposes patients
to continued drinking and perpetuates the cycle of AUD
and liver injury [15].
Major associations, such as the European Association
for the Study of the Liver and the American Association
for the Study of Liver Diseases, have stressed the need to
address alcohol use in infected patients. While aiming for
complete abstinence is desirable, reduction of drinkingarticle distributed under the terms of the Creative Commons Attribution
by/4.0), which permits unrestricted use, distribution, and reproduction in
operly credited. The Creative Commons Public Domain Dedication waiver
/1.0/) applies to the data made available in this article, unless otherwise stated.
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for Disease Control and Prevention has recently recom-
mended to systematically screen HCV(+) patients for alco-
hol use and to treat problem drinkers accordingly [19].
However, no direct recommendation regarding the pre-
ferred treatment options for AUD in HCV(+) patients has
been issued, except for brief counseling and referral to ap-
propriate care [19].
In the general population, psychotherapeutic ap-
proaches for AUD play an important role in reducing alco-
hol use and attaining abstinence. However, when given
alone, such interventions are not always successful, and
relapse rates after long-term treatment exceed 40–70 per-
cent [20-23]; available medications to treat AUD are thus
critical in relapse prevention strategies [24,25]. Research
evidence demonstrates that physicians without extensive
specialized training can effectively prescribe such medica-
tions, leading to a reduction in heavy alcohol drinking and
increased days of abstinence [26].
However, from a clinical point of view, unique factors
belonging to the patients infected with HCV complicate
AUD drug therapy, making this population different
from the HCV(-) drinkers. Aside from the existing epi-
demiological and etiological association described above,
the baseline hepatic vulnerability and possible additional
hepatotoxicity caused by certain compounds used to
treat AUD make their utilization in HCV(+) drinkers po-
tentially more challenging than in HCV(-) ones. The
natural history of chronic HCV infection, known to
cause waxing and waning of liver enzyme elevations over
time, can confound medication studies, especially safety
monitoring of a therapeutic challenge in a given subject
[27]. Specific issues stem from possible interactions be-
tween the drugs used to treat AUD and the ones used to
treat HCV infection, both at a pharmacological and psy-
chiatric level. We thus propose in this article to system-
atically review the evidence on the pharmacological




The literature search was conducted in the following elec-
tronic databases: MEDLINE, Embase, PsycINFO, and the
Cochrane Central Register of Controlled Trials. The
search was restricted to English- and French-language ar-
ticles published from 1993 to December 2013 (see Table 1
for the detailed search strategy). Additional search was
conducted on clinicaltrials.gov (included in Table 1) to
identify undergoing, unpublished trials. The search strat-
egy was elaborated with the input of a medical library spe-
cialist (see acknowledgments). The methodological aspect
of this article is based on Grimshaw’s “A Knowledge Syn-
thesis Factor,” available online at the Canadian Institutesof Health Research website [28]. Titles and abstracts were
sorted and two MD-level reviewers (AT and SB) independ-
ently evaluated potentially relevant studies. Additionally,
related articles and their references were reviewed manu-
ally to identify additional eligible studies. A third re-
searcher (DJA) was available if any discrepancy occurred
between the searches led by the reviewers.
Eligibility criteria
To be included, studies had to evaluate the efficacy or
safety of drug therapy for AUD in participants infected
with HCV. Given the paucity of data and to avoid the
exclusion of studies with relevant but less-than-optimal
data, we chose broad inclusion criteria.
All types of studies were included: randomized con-
trolled trials (RCTs); observational, retrospective, and
prospective studies; and case reports. Post-hoc analysis
of primary studies and studies where efficacy and safety
of a given drug were not the primary measured out-
comes were also included. Reviews were excluded.
Participants were either inpatients or outpatients, 18
years of age or older, diagnosed with HCV infection at
any stage of the disease, with concomitant AUD.
Data extraction and analysis
When available, the following data were retrieved from the
included studies: authors, publication year, study design,
length of the study, inclusion and exclusion criteria, sample
size, characteristics of participants, type of intervention,
measured outcomes, follow-up rate, and compliance.
Results
We identified 421 potentially eligible studies. Of these,
418 were excluded after reviewing titles and/or abstracts
because they had no relevance to the subject of this re-
view or because they were duplicates. No studies were
excluded because of study design or participant charac-
teristics (see Figure 1 for selection process). Out of the
three selected studies, two were observational studies on
disulfiram therapy and one was an RCT on baclofen.
Neither of the three studies reported data on partici-
pants with acute HCV infection (see Table 2 for detailed
search results).
The separate search on clinicaltrials.gov yielded 149
results, one of which (NCT01008280) was of interest
and fitted our inclusion criteria: an ongoing RCT asses-
sing the efficacy of baclofen. It was not formally in-
cluded in our analysis for there are no published results
yet (not included in Table 2 or Figure 1).
Included studies
The use of disulfiram in HCV(+) individuals with AUD
was first assessed by Saxon et al. in a study focusing on
this medication’s safety [27]. They reported a prospective
Table 1 Search strategy to identify studies, by database




MEDLINE (Search terms via Pubmed)* (“Hepatitis C” OR HCV) AND (“alcohol dependence” OR alcoholism
OR “alcohol-dependent”) AND (pharmacological treatment OR drug
therapy OR disulfiram OR naltrexone OR acamprosate OR baclofen
OR ondansetron OR topiramate)
138 3
Embase (MeSH terms via Ovid) #1: Hepatitis C OR Hepatitis C virus 92110 3 (duplicates)







#9: #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 60923
#10: #1 AND #9 237
#11: Limit #10 to human studies and year 1993 to
December 2013 (final result)
225
PsycINFO (MeSH terms via Ovid) #1: Hepatitis 1821 2 (duplicates)
#2: Alcoholism 24628
#3: #1 AND #2 62
#4: Limit #3 to human studies and year 1993 to December 2013 54
Cochrane Central Register of Controlled
Trials (MeSH terms via Ovid)
#1: Alcoholism 2130 0
#2: Hepatitis C 707
#3: #1 AND #2 4
#4: Limit #3 to year 1993 to December 2013 4
Clinicaltrials.gov (unpublished) “Hepatitis C” AND “alcohol” 149 1 (underway; no results yet)
*limits: human studies and studies between 1993 and December 2013.
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(according to DSM-IV criteria) and concomitant ele-
vated liver function test results and/or serologic evi-
dence of HCV infection. All participants received
disulfiram. Eighteen out of the 57 subjects were
HCV(+). Sequential liver function tests were conducted
at baseline and for up to 3 months while patients were
taking the medication. The efficacy of the drug was not
a measured outcome. The presence of aspartate trans-
aminase (AST) or alanine transaminase (ALT) values
above 200 u/l led to the exclusion of two subjects as de-
termined in the protocol. Of the 18 HCV(+) partici-
pants, four exhibited marked transaminase elevations
during the trial, as defined by transaminase levels greater
than twice the baseline and three times the normal
range. In comparison, only 1 out of 39 subjects without
HCV had a marked increase of those enzymes. Although
this comparison was not statistically evaluated, one of
the conclusions of the report was that under disulfiram
treatment, HCV(+) alcohol-dependent participants were
more likely to have significant transaminase elevationscompared to HCV(-) participants with abnormal baseline
liver enzymes. The authors also stated that their findings
support the cautious use of this medication with regular
laboratory monitoring in patients who present with ele-
vated liver enzymes at baseline [27].
A second safety study [29] retrospectively assessed
transaminase levels in 26 HCV(+) and 20 HCV(-) sub-
jects receiving 1500 mg of weekly supervised disulfiram
for 12 months (disulfiram was given in doses either of
500 mg three times weekly or of 750 mg two times
weekly). Groups were similar regarding age, ethnicity,
and baseline mean AST and ALT levels. Both groups
also had similar compliance rates (around 70%) with
disulfiram. Within-group analysis revealed no statisti-
cally or clinically significant increase (defined by three
times the upper normal limit) across time in mean AST
and ALT levels at 3, 6, 9, and 12 months for the HCV(+)
group. However, AST levels in HCV(-) subjects statisti-
cally dropped at 6 and 12 months (p < 0.05). Between-
group comparison, using a nonpaired mean, also failed to
identify a statistical difference in liver enzyme levels at any
Hand-searched 
potentially eligible 
studies (n = 0)
Potentially eligible studies identified 
through database searches (N = 421)
- MEDLINE = 138
- Embase = 225
- PsycINFO = 54
- Cochrane Central Register 
of Controlled Trials = 4
Exclusion of
duplicate study 
reports (n = 18)
Potentially eligible 
study reports (n = 403) 
Excluded
Did not meet 
inclusion criteria 
(n = 400)
Included studies (n = 3)
Figure 1 Flow chart of the selection process of published studies.
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HCV(-) participants. The authors concluded that HCV(+)
participants were not more prone to disulfiram-induced
hepatotoxicity when compared with HCV(-) subjects.
Overall, the report also concluded that supervised
disulfiram may be used in HCV(+) AUD patients, with
close monitoring of liver enzymes. Of interest, even
though no clinically relevant elevations of liver enzymes
or need for disulfiram discontinuation occurred, three
out of 26 HCV(+) individuals reached two times the
upper normal limit, as opposed to none in the HCV(-)
group. Moreover, 14 and 16, respectively, out of the 26
HCV(+) participants, experienced AST and ALT eleva-
tions compared to their baseline values. However, these
results were not statistically different from the ones in
the HCV(-) group.
More recently, Addolorato et al. reported reported a
study of 84 subjects diagnosed with alcohol dependence
according to DSM-IV, with comorbid diagnosis of viral
and/or alcoholic cirrhosis [30]. A post-hoc analysis of a
subsample of 24 participants who were also suffering
from chronic HCV infection was then undertaken by
Leggio et al. [31]. HCV(+) alcohol-dependent cirrhotic
patients were randomized in two groups; 12 received 30
mg/day of baclofen and the other 12 received placebo.
There were no statistical differences in baseline charac-
teristics, including on alcohol dependence’s duration and
severity. Regarding the primary outcome, subjects in the
baclofen group achieved higher rates of abstinence com-
pared to placebo group (83.3% vs. 25.0%; p = 0.0123).The baclofen group also showed a greater increase of al-
bumin values from baseline (p = 0.0132) and a trend to-
ward decrease in international normalized ratio (INR)
levels that did not reach significance (p = 0.0716). No
difference was observed in AST, ALT, gamma-glutamyl
transferase (GGT), and creatinine values. Dropout rates
and side effects were comparable; no participant discon-
tinued the drug for safety reasons. The subsample of 24
HCV(+) alcohol-dependent subjects had comparable
baseline characteristics to the initial sample (84 alcohol-
dependent participants), except for higher initial ALT
and AST levels. Overall, the authors concluded that bac-
lofen was more effective than placebo in the achieve-
ment and maintenance of alcohol abstinence, and in the
improvement of some liver function tests in alcohol-
dependent HCV(+) cirrhotic patients.
A fourth study (NCT01008280 on clinicaltrial.gov)
evaluating the efficacy and safety of 12 weeks of 30 mg
daily of baclofen in HCV(+) subjects with AUD is pres-
ently underway. The U.S. multisite, double-blind, ran-
domized placebo-controlled trial was expected to enroll
180 veterans and be completed in June 2014.
Discussion
A critical analysis of the identified trials underlines a
number of interesting findings and issues that remain
unresolved. The two included observational studies of
57 and 46 participants, respectively, assessed the safety
of disulfiram in HCV(+) individuals. Both study groups
concluded that disulfiram could be a safe therapeutic
Table 2 Included published studies assessing the pharmacological management of AUD in participants infected with HCV
References Study type and duration Participants Intervention Measured outcomes Results Adverse events
Martin et al. [29] Retrospective controlled
study, 12 months
26 HCV(+) men versus





Hepatic safety of disulfiram
as measured by AST/ALT
1–No statistically or clinically
significant elevations of
AST/ALT for the HCV(+)
group at any time point
No patients taken off disulfiram;
no subjects reached 3 times to
upper limit for AST/ALT
1–In HCV(+) group over time;
2–Compared to HCV(-) group
2–Between-group means
were identical at all
time points
Saxon et al. [27] Prospective study
of 3 months
57 male veterans; 18 HCV(+)
and 39 HCV(-) with elevation
of AST/ALT
Disulfiram Hepatic safety of disulfiram
as measured by elevations
in AST/ALT in
Clinically relevant elevation
(2x the baseline and 3x
the normal) in:
No hepatitis or hepatic failure,
although some patients did





Leggio et al. [31] Post-hoc analysis of a randomized
placebo-controlled trial of cirrhotic
patients [30], 12 weeks
24 HCV(+) cirrhotic patients;





1–Efficacy of baclofen in
HCV(+) cirrhotic patients
1–Significantly more abstinence
in baclofen group (83,3% vs.
25%; p = 0,0123)
No hepatic or renal adverse
events. General side effects
were not more frequent
compared to placebo
2–Hepatic safety of baclofen
as measured by biochemical
liver function tests
2–Higher albumin and trend
toward decreased INR in baclofen
group; no effect on AST/ALT/GGT
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ranted because of possible hepatotoxicity [27,29]. The third
study was a 24-HCV(+) patient, randomized, placebo-
controlled trial, which concluded that baclofen was ef-
fective in maintaining abstinence. The drug seemed safe
in this population, since no elevation of biochemical
markers of liver injury was observed. The results even
showed improvements in biological markers, when
compared to placebo [31].
A number of limitations can be identified in the first
disulfiram study [27]. It was not placebo controlled, nor
was there a control group comprised of subjects with
normal liver function. Also, there was no statistical com-
parison of the biological markers of disulfiram-induced
hepatic injury between HCV(+) and HCV(-) subjects,
which may possibly be explained by the lack of power
related to the limited number of subjects in this study.
Moreover, although baseline values of hepatic function
tests were provided for the entire sample, those values
were not specifically given for HCV(+) individuals. Other
limitations include the absence of information regarding
dose and compliance to disulfiram, and lack of assessment
of alcohol intake by participants. Consequently, the draw-
ing of strong conclusions regarding disulfiram’s safety is
difficult. Both the cause and significance of the enzyme el-
evations in HCV(+) subjects are not easy to interpret in
the study. Such elevations could be related to alcohol con-
sumption, hepatitis C per se, or other characteristics not
measured and controlled at baseline. The study is still in-
formative when considering that a relatively small portion
of subjects with an HCV(+) status and/or elevated base-
line transaminases developed marked liver enzymes eleva-
tions while taking disulfiram, and none developed severe
adverse events.
In the second study [29], the retrospective design pre-
cludes the drawing of definitive conclusions and questions
the significance of enzyme elevations. More than half of the
data were missing for the 6- to 12- month period. No ex-
clusion criteria were given and no method to assess alcohol
intake was applied. On the other hand, the presence of a
control group, the HCV(-) AUD participants, with similar
baseline characteristics and compliance rates, allows for
more reliable conclusion regarding the safety of disulfiram
in HCV(+) patients suffering from AUD. The absence of se-
vere transaminase elevations and lack of adverse events is
reassuring, as is the absence of discontinuation because of
hepatotoxicity.
Some common limitations can be identified in both
disulfiram studies. Small sample sizes often preclude obser-
vation of rare but potentially serious adverse events. The
sole use of AST and ALTas an accurate indicator of hepatic
injury may be criticized [32]. However, the cut-off of three
times the upper limit of normal has an experimental and
clinical basis [33]. The absence of randomization, placebocontrol, and lack of information regarding effectiveness are
also limitations, but both studies remain highly useful as
the only ones to have addressed the clinical use of
disulfiram therapy in individuals infected with HCV.
The trial assessing baclofen [31] also contains limitations,
including the small sample size and those inherent to post-
hoc analysis. It would have been interesting to compare the
final liver function tests of the HCV(+) subsample to those
of the original sample. This would have allowed the com-
parison of drug safety and effectiveness between HCV(+)
cirrhotic subjects and HCV(-) cirrhotic participants. An-
other limitation is the fact that the results of this study pri-
marily apply to cirrhotic patients. However, safety of
baclofen with these patients is reassuring for individuals
with less severe liver disease, and conclusions about baclo-
fen’s safety can probably be inferred to all HCV(+) patients.
These limitations taken into account, this study seems to
provide safety and preliminary efficacy data on baclofen in
alcohol-dependent cirrhotic patients suffering from HCV
infection. It is the only identified RCT assessing pharmaco-
logical management in this population, and the only one
using various types of liver function tests, providing a more
accurate estimate of hepatic integrity.
Unfortunately, in light of our search, no other studies
specifically assessed AUD treatment options in a particular
sample of HCV-infected individuals. Some authors agree
that the risk of disulfiram liver injury appears much lower
than the one caused by excessive alcohol consumption
with concurrent HCV infection [10,29]. However, its
known limited efficacy in the general population [34-38]
and the above-mentioned limitations in the two trials pre-
vent any recommendation regarding disulfiram’s place in a
treatment algorithm. Baclofen is the only molecule that
has been assessed in an RCT of HCV(+) individuals, and a
recent systematic review [39] concluded that the drug
could be considered as the preferred option in patients
with moderate to severe liver disease in whom other
pharmacological treatments are not safe. However, only a
few studies have assessed baclofen in the general popula-
tion, with encouraging yet mixed results [30,40,41], which
further limits the sole above-mentioned study [31]. The
registered clinical trial assessing baclofen in HCV-infected
veterans (NCT01008280) will perhaps answer a few more
pending questions.
Several other studies related to the object of this review
but not fitting our search criteria merit mention. One ran-
domized placebo-controlled trial [42] and its associated
open-label extension phase [43] both reported promising
results regarding extended-release naltrexone’s hepatic
safety in the treatment of opioid dependence in a sample
of adults, which turned out to have high rates (over 80%)
of mild to moderate chronic HCV infection. Although
HCV(+) subjects were not specifically studied, it is worth
noting that no serious adverse events were recorded. A
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naltrexone given for opioid and/or AUD and its impact on
antiretroviral effectiveness in an HIV population has also
been conducted. The authors reported very few enzyme
elevations during follow-up and concluded that oral nal-
trexone was a safe option. While this was not the focus of
the study, a strong proportion of the sample (57%) was
co-infected with HCV. Oral naltrexone is known for its
hepatotoxicity but may merit further assessment as to its
role in the treatment of subjects with pre-existent and on-
going liver damage. The same can be said about extended-
release naltrexone, especially since there is no clear evi-
dence for its hepatoxicity [45,46].
The present systematic review has some significant limi-
tations, including the lack of mechanism to exclude publi-
cation bias, as no search for unpublished studies was
undertaken other than on clinicaltrials.gov. The small sam-
ple size, heterogeneous groups of patients, and variability of
study design make the comparison of studies quite limited,
and a meta-analysis was impossible to realize. Also, non-
English and non-French studies were not included.
The lack of trials may be explained partly by the obsta-
cles in treatment accessibility in AUD patients infected
with HCV. Substance-addicted HCV(+) patients have
known inherent characteristics such as concomitant
mental illness, disorganized lifestyle, and poor socioeco-
nomic status, which greatly limit the accessibility and
success of adequate treatment [9]. Additionally, these pa-
tients also face barriers at the provider level and system
level [47]. Until recently, the inclusion of such patients in
studies was even more limited, and often not encouraged.
This seems to be somewhat paradoxical since they repre-
sent a substantial proportion of patients infected with
HCV. Moreover, treating HCV and AUD concomitantly is
a relatively recent practice. Thus, the question of the man-
agement of such patients is a new one, explaining perhaps
the absence of studies examining this specific situation.
The advent of novel antiviral treatments for chronic
hepatitis C makes shorter and interferon-free regimens
possible. The combinations of direct-acting antiviral
agents have fewer psychiatric side effects compared to
previous treatment options. Concerns regarding interac-
tions between alcohol and HCV treatment may thus seem
of a lesser importance. However, interferon-free regimens
will not be available or suit every patient. Moreover, even
with the availability of these highly effective therapies, few
patients actually receive treatment, multiple barriers and
low rates of eligibility still being the norm [48-50]. Heavy
alcohol consumption is constantly reported, even with
newer treatment regimens, as one of the principal barrier
to HCV treatment and is considered a relative contraindi-
cation to antiviral treatments [49,51]. Therefore, treating
AUD remains an important goal to pursue to maximize
availability to newer HCV infection treatment options.Additional studies assessing the pharmacological man-
agement of AUD in HCV(+) individuals are needed, par-
ticularly high-quality RCTs evaluating already-studied
molecules and other options, such as acamprosate. The lat-
ter molecule could be an interesting research target, given
its known efficacy and hepatic safety [52]. Nalmefene,
gabapentin, and topiramate, all promising therapeutic op-
tions for alcohol dependence (but not FDA-approved for
this purpose), could also be the focus of future research.
Nalmefene, a drug acting on the opioid system, is not
known to cause liver injury in the several studies to date
[53]. Gabapentin, an antiepilectic, has an extrahepatic me-
tabolism and is considered to have no adverse events on
the hepatic system [54]. Topiramate, also an antiepileptic,
rarely causes liver enzyme elevations and is considered
safe, at least in dosage used for epilepsy. Studies examining
the pharmacological management of AUD with concomi-
tant antiviral therapy would be interesting, considering the
potential combined effect of both treatment regimens on
hepatic integrity and mental health, and potential drug-
drug interactions. There is also a need for qualitative and
quantitative studies to evaluate the benefits of an inte-
grated approach in the treatment of comorbid hepatitis C
and AUD. Such approaches, combining mental health care
and medical care, are usually beneficial in the management
of such difficult-to-treat populations with similar comor-
bidities, such as SUD and hepatitis [55-57].
Conclusion
Co-occurrence of HCV infection and AUD is frequently
encountered, and patients afflicted by both conditions are
at increased risk of liver disease and subsequent mortality.
There is, unfortunately, a small number of studies that
examine pharmacological options for AUD treatment in
HCV patients. Baclofen specifically showed promising re-
sults, while disulfiram’s results, though encouraging, are
greatly limited by study designs. Due to the paucity of
data, no clinical recommendations regarding pharmaco-
logical interventions can be made. The present review and
its conclusion stress the need for future research, includ-
ing studies to examine the efficacy of other existing
pharmacological options for AUD in HCV(+) individuals.
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